Parliamentary Exchange on Orphan and Ultra-Orphan Medicines

Asked by Lord Hunt of Kings Heath on 14th December 2016

To ask Her Majesty’s Government what assessment they have made to determine the extent to which NHS England’s prioritisation process provides a fair assessment for (1) non-orphan, (2) orphan, and (3) ultra orphan, medicines.

 Answered by: Lord Prior of Brampton on 19th December 2016

NHS England is waiting for the outcome of the current joint National Institute for Health and Clinical Excellence (NICE) and NHS England consultation on proposed changes to arrangements for evaluating and funding drugs and other health technologies, which are appraised through NICE’s technology appraisal and highly specialised technologies programmes.

The consultation is due to close on 13 January. Once the responses to the consultation have been reviewed, NHS England and NICE will consider whether any changes to the way orphan drugs are evaluated should be made.

Tagged with

Published 20. December 2016 in News UK